1 Min Read
Nov 6 (Reuters) - Bayer AG
* Submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.